Latest News
A research team have discovered a new mechanism by which elovanoids may protect retinal and brain cells against neurodegenerative diseases such as Alzheimer’s and age-related macular degeneration.
NHS England have approved the use of cannabis-based medicines for the first time. Epidyolex can now be prescribed to children with severe epilepsy syndromes and Sativex can be prescribed to individuals with multiple sclerosis.
Chinese pharmaceutical firm, Shanghai Green Valley Pharmaceuticals, has gained conditional approval from the country’s regulatory agency for oligomannate as a treatment for mild-to-moderate Alzheimer’s disease.
Journal Articles
In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.
Take a look behind the scenes of a study published in Brain, as we ask Dr Ryan D’Arcy about the establishment of brain vital signs for concussion-related impairments.
Discover more about an ongoing, multicenter registry that provides real-world evidence regarding ataluren use in nonsense mutation Duchenne muscular dystrophy patients in this research article.
Autoimmune
Could hyaluronic acid contribute to chronic white matter injury?
Can living in a sunnier climate in your youth reduce the risk of MS?
Cerebrovascular disease
Traumatic microbleeds may predict worse outcomes following head injury
Blood pressure changes in mid-30s linked to poorer brain health
Age-related cognitive changes may be reduced with intensive blood pressure control
CNS/PNS/SNS
Neuroprosthetic exoskeleton allows tetraplegic patient to utilize his limbs
Traumatic CNS injury and the inflammatory stem cell niche: an interview with Aileen Anderson
Electrical patterns in ‘mini-brains’ can’t be distinguished from premature babies, study reveals
Cognitive/neurodegenerative disorders
Translating genetic data in Alzheimer’s into potential therapies with Owen Peters
Alzheimer’s and AMD: could elovanoids be a new therapeutic target?
Circadian disruption in the prodromal stages of dementia with Marco Brancaccio
Demyelinating disease
Cannabis-based medicines for epilepsy and multiple sclerosis approved by NHS
Unraveling the heterogeneity of oligodendrocytes with Ana Mendanha Falcão
Development and pediatrics
SfN19: Brain organoids advance studies of neural development, research suggests
SfN19: Advances in autism research could pave way for early intervention and treatment
Epilepsy and seizure
Cannabis-based medicines for epilepsy and multiple sclerosis approved by NHS
Dynorphin-based gene therapy demonstrates long-term suppression of seizures
Epidyolex® receives marketing authorization from the EMA for seizures
Genetics
Translating genetic data in Alzheimer’s into potential therapies with Owen Peters
Rare gene variant APOE3ch may hold clues to preventing Alzheimer’s disease
Genetic therapies for neurodegenerative diseases: an interview with Sarah Tabrizi
Headache
Emgality® achieves primary and secondary outcomes in Phase III trial for migraines
Acute migraine: novel therapy shows promise in Phase III trial
Why are migraines more common in women? New sex-specific insights revealed
Immune disorders and inflammation
SfN19: Uncovering the complex interplay between microglia, neuroinflammation and disease pathology
Inflammatory disease and anxiety: could endocannabinoids be a mechanism of comorbidity?
FENS 2018: Immune system offers new way of treating Alzheimer’s disease
Infection
Could a bacterial polysaccharide suppress fatal brain inflammation?
Link between Alzheimer’s disease and periodontal bacteria gains traction
Injury/trauma
SfN19: How might the gut–brain connection impact brain health in mice?
Tranexamic acid could reduce head injury deaths by ‘hundreds of thousands’
Traumatic microbleeds may predict worse outcomes following head injury
Movement disorders
Neuroprosthetic exoskeleton allows tetraplegic patient to utilize his limbs
Parkinson’s progression could be slowed down by drug that treats enlarged prostate
Ofatumumab demonstrates superiority over Aubagio® for relapsing MS: industry news round-up
Neuro-ophthalmology
Gene therapy breakthrough allows mice to regain sight
Could an eye scan detect signs of Alzheimer's disease?
Vision in Alzheimer's disease: a focus on the anterior afferent pathway
Neurometabolic
Epigenetics, opioids and immune regulation: interviews from SfN17
Jeffrey Iliff: glymphatics, Alzheimer’s and future directions
SfN17: Neurodegeneration and the microbiome – new research highlights
Neuromuscular
New genetic suspects identified for ALS and FTD
Novel discovery in motor neuron disease may pave the way for future treatments
Neuropsychiatry
World Mental Health Day: facts, figures and the flaws of academia
Could psychiatric disorders be triggered by air pollution?
Addiction: a compulsive interplay between drugs, cues and habits
Oncology/tumor
Can artificial intelligence speed up brain tumor diagnosis?
Liquid biopsy could predict prognosis of glioblastoma, study suggests
High-grade gliomas may hijack signals from neurons to drive their own growth
Pain
Emgality® achieves primary and secondary outcomes in Phase III trial for migraines
Advances in migraine genetics, neurobiology and treatment
Acute migraine: novel therapy shows promise in Phase III trial
Sleep
Circadian disruption in the prodromal stages of dementia with Marco Brancaccio
Could circadian rhythms influence immune response efficiency in mice?
